Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Hypoglycemia in Patients With Type 2 Diabetes Treated With Oral Antihyperglycemic Agents Detected by Continuous Glucose Monitoring: A Multi-Center Prospective Observational Study in Croatia (CROSBI ID 276404)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Baretić, Maja ; Bralić-Lang, Valerija Hypoglycemia in Patients With Type 2 Diabetes Treated With Oral Antihyperglycemic Agents Detected by Continuous Glucose Monitoring: A Multi-Center Prospective Observational Study in Croatia // BMC endocrine disorders, 20 (2020), 11; 35-43. doi: 10.1186/s12902-020-0518-5

Podaci o odgovornosti

Baretić, Maja ; Bralić-Lang, Valerija

engleski

Hypoglycemia in Patients With Type 2 Diabetes Treated With Oral Antihyperglycemic Agents Detected by Continuous Glucose Monitoring: A Multi-Center Prospective Observational Study in Croatia

Background: Hypoglycemia in type 2 diabetes mellitus (T2DM) is still unsolved issue. The aim of this study was to investigate hypoglycemia in T2DM in participants treated with oral antihyperglycemic agents using different glucose cut-off values and to explore influence of different therapies. Methods: This multi-center prospective observational study included participant with T2DM from primary care offices across Croatia treated with antihyperglycemic agents who were monitored using professional continuous glucose monitoring (CGM) device (iPro™2). Hypoglycemia was defined as at least 1% of the monitored period spent in the hypoglycemic range and/or area under the curve of glycemia registered ever under the defined cut-off value. The higher upper limit of blood glucose cut-off value was 3.9 mmol/L (70 mg/dL) and the lower one 3.0 mmol/L (54 mg/dL). Results: Study included 94 participants. Median hemoglobin A1C levels, age, T2DM duration, body mass index, and CGM use duration were 7 (5.8- 11.5) %, 65 (40-86) years, 7 (1-36) years, 30.4 (21.3-41.5) kg/m2 and 6 (1-7) days, respectively. Fifty participants were treated with sulfonylurea, primarily gliclazide (84%). The percentage of participant with hypoglycemia based on the higher cut-off value was 42.6% vs. 16% based on the higher cut-off value. The percentage of participant with nocturnal hypoglycemia (23 PM to 06 AM) was significantly lower among participant with hypoglycemia based on the higher cut-off value compared to lower one (7.8% vs. 22.9%). Sulfonylurea treatment did not influence the occurrence of hypoglycemia. Analysis of the data from participants having hypoglycemia based on the lower cut-off value pointed to other possible risk factors for hypoglycemia like prolonged overnight fasting, physical activity, alcohol consumption, and concomitant therapy with angiotensin-converting enzyme inhibitors. Conclusions: In participant with T2DM treated with oral antihyperglycemic agents hypoglycemia based on the blood glucose cut-off value of 3.9 mmol/L was more prevalent, but with less nocturnal hypoglycemia. Sulfonylurea therapy was not risk factor for hypoglycemia regardless of cut-off value. In participants having hypoglycemia based on the blood glucose cut-off value of 3.0 mmol/L some other possible factors were identified related to concomitant therapy, nutrition and daily habits.

Continuous glucose monitoring ; Hypoglycemia ; Oral antihyperglycemic agents ; Type 2 diabetes.

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

20 (11)

2020.

35-43

objavljeno

1472-6823

10.1186/s12902-020-0518-5

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost